Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Efficacy and safety analysis of avapritinib in children with RUNX1::RUNX1T1 positive-acute myeloid leukemia with KIT mutations].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 14 Apr 2026

Zheng F Y, Ding M M, Lu A D, Jia Y P, Zeng H M, Zhang L P

Abstract excerpt

Objective: To evaluate the efficacy and safety of avapritinib in children with RUNX1::RUNX1T1-positive acute myeloid leukemia (AML) with KIT mutations. Methods: Clinical data on children with RUNX1::RUNX1T1-positive AML with KIT mutations who received avapritinib at the Department of Pediatrics, Peking University People's Hospital, from September 2022 to June 2025 were collected. The overall response rate (ORR),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factor Alpha 2 Subunit

Share to Leukemia, Myeloid, Acute

Share to Proto-Oncogene Proteins c-kit

Share to Pyrazoles

Share to RUNX1 Translocation Partner 1 Protein

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42161658
DOI: 10.3760/cma.j.cn121090-20251027-00482
PMCID: PMC13195544

Genes

RUNX1
RUNX1T1
KIT
EFS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Efficacy and safety analysis of avapritinib in children with RUNX1::RUNX1T1 positive-acute myeloid leukemia with KIT mutations].PMID 42161658Read ↗

Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a case reportSemantic proximity Read ↗

Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.Semantic proximity Read ↗

[The efficacy and safety of avapritinib in the treatment of molecular biologically positive core binding factor-acute myeloid leukemia with KIT mutation after allogeneic hematopoietic stem cell transplantation].Semantic proximity Read ↗

Rapid response to avapritinib of acute myeloid leukemia with t(8;21) andKITmutation relapse post allo-HSCTSemantic proximity Read ↗

Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemiaSemantic proximity Read ↗

[Analysis of the therapeutic effect of avatinib bridged allogeneic hematopoietic stem cell transplantation on 7 cases of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia with KIT mutations].Semantic proximity Read ↗

Avapritinib is Effective for Treatment of Minimal Residual Disease in Acute Myeloid Leukemia with t (8;21) and KIT mutation Failing to Immunotherapy After Allogeneic Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Avapritinib for Systemic Mastocytosis.Semantic proximity Read ↗

Avapritinib for advanced systemic mastocytosis.Semantic proximity Read ↗

Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.Semantic proximity Read ↗

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.